Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Trypanocidal and cysteine protease inhibitory activity of isopentyl caffeate is not linked in Trypanosoma brucei.

Steverding D, da Nóbrega FR, Rushworth SA, de Sousa DP.

Parasitol Res. 2016 Aug 18. [Epub ahead of print]

PMID:
27535679
2.

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.

Pillinger G, Loughran NV, Piddock RE, Shafat MS, Zaitseva L, Abdul-Aziz A, Lawes MJ, Bowles KM, Rushworth SA.

Oncotarget. 2016 May 11. doi: 10.18632/oncotarget.9289. [Epub ahead of print]

3.

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.

Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ, Bowles KM.

Lancet Haematol. 2015 May;2(5):e204-11. doi: 10.1016/S2352-3026(15)00046-0. Epub 2015 Apr 14.

PMID:
26688095
4.

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA.

Sci Rep. 2015 Aug 21;5:12949. doi: 10.1038/srep12949.

5.

Oxidative stress responses and NRF2 in human leukaemia.

Abdul-Aziz A, MacEwan DJ, Bowles KM, Rushworth SA.

Oxid Med Cell Longev. 2015;2015:454659. doi: 10.1155/2015/454659. Epub 2015 Mar 30. Review.

6.

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM.

Cell Cycle. 2015;14(14):2367-75. doi: 10.1080/15384101.2014.998067. Epub 2015 Jan 7.

7.

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.

Zaitseva L, Murray MY, Shafat MS, Lawes MJ, MacEwan DJ, Bowles KM, Rushworth SA.

Oncotarget. 2014 Oct 30;5(20):9930-8.

8.

Understanding life and death decisions in human leukaemias.

MacEwan DJ, Barrera LN, Keadsanti S, Rushworth SA, Shah NM, Yuan T, Zaitseva L.

Biochem Soc Trans. 2014 Aug;42(4):747-51. doi: 10.1042/BST20140127.

PMID:
25109952
9.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

10.

Ibrutinib in relapsed chronic lymphocytic leukemia.

Rushworth SA, MacEwan DJ, Bowles KM.

N Engl J Med. 2013 Sep 26;369(13):1277-8. doi: 10.1056/NEJMc1309710#SA2. No abstract available.

PMID:
24066760
11.

Understanding the role of NRF2-regulated miRNAs in human malignancies.

Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ.

Oncotarget. 2013 Aug;4(8):1130-42. Review.

12.

Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.

Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ.

Cell Cycle. 2013 Jul 1;12(13):2144-53. doi: 10.4161/cc.25251. Epub 2013 Jun 11.

13.

The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.

Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ.

Blood. 2012 Dec 20;120(26):5188-98. doi: 10.1182/blood-2012-04-422121. Epub 2012 Oct 17.

14.

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.

Cell Signal. 2013 Jan;25(1):106-12. doi: 10.1016/j.cellsig.2012.09.008. Epub 2012 Sep 11.

PMID:
22975686
15.

Bortezomib induces heme oxygenase-1 expression in multiple myeloma.

Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ.

Cell Cycle. 2012 Jun 15;11(12):2248-52. doi: 10.4161/cc.20343. Epub 2012 Jun 15.

16.

Understanding the role of miRNA in regulating NF-κB in blood cancer.

Rushworth SA, Murray MY, Barrera LN, Heasman SA, Zaitseva L, Macewan DJ.

Am J Cancer Res. 2012;2(1):65-74. Epub 2011 Nov 21.

17.

Micro RNAs as a new therapeutic target towards leukaemia signalling.

Murray MY, Rushworth SA, MacEwan DJ.

Cell Signal. 2012 Feb;24(2):363-8. doi: 10.1016/j.cellsig.2011.09.021. Epub 2011 Sep 25. Review.

PMID:
21978953
18.

Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.

Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, Macewan DJ.

Oncotarget. 2011 Sep;2(9):658-68.

19.

TNF mediates the sustained activation of Nrf2 in human monocytes.

Rushworth SA, Shah S, MacEwan DJ.

J Immunol. 2011 Jul 15;187(2):702-7. doi: 10.4049/jimmunol.1004117. Epub 2011 Jun 13. Erratum in: J Immunol. 2011 Dec 1;187(11):6160.

20.

Silencing FLIP(L) modifies TNF-induced apoptotic protein expression.

Zaitseva L, Rushworth SA, MacEwan DJ.

Cell Cycle. 2011 Apr 1;10(7):1067-72. Epub 2011 Apr 1.

PMID:
21403465
Items per page

Supplemental Content

Loading ...
Write to the Help Desk